L’Oreal’s Anti-Wrinkle RevitaLift Products Are Unlawfully Marketed Drugs – Class Action Complaint

摘要

L ’Oreal USA Inc. is marketing unap- proved drugs in defance of federal and California food and drug law, which in turns puts it in violation of Cali- fornia’s Unfair Competition Law, according to a proposed class action in California’s Central District. Filed at the end of February, the suit fo- cuses on the L’Oreal Paris RevitaLift line. “On the front of each and every Product package, where consumers cannot miss it, Defendant represents that the Products will reduce or repair wrinkles,” plaintif Na- taliya Borchenko says.